Dr. Ghali on the potential of antibody-drug conjugates in variant histology bladder cancer

In this video, Fed Ghali, MD, a urologic oncology fellow at the University of Washington, says that variant histology bladder cancers express Nectin-4 and Trop-2, which are cell surface targets of the FDA-approved antibody-drug conjugates, enfortumab-vedotin (Padcev) and sacituzumab govitecan (Trodelvy), respectively. Ghali presented the abstract, “Antibody-drug conjugates and variant histology muscle-invasive bladder cancer: are the targets present in primary and/or metastatic tumors?” at the 2022 AUA Annual Meeting (abstract PD53-09).